The present invention provides a production method capable of efficiently synthesizing an SF.sub.5 group-containing compound, or the like. The present invention is a method for synthesizing an SF.sub.5 group-containing compound represented by the general formula (1) from a thioaryl compound represented by the general formula (2) [A.sup.1 is an aryl group or a heteroaryl group; G.sup.1 is SH, SCN, SF.sub.3, SSR.sup.1, SCOR.sup.2, SR.sup.3, SF.sub.2R.sup.4, SSi(R.sup.5).sub.3, SPO(R.sup.6).sub.2, (N-phthalimidyl)thio group, or a thianthrenium group (R.sup.1 is an aryl group or a heteroaryl group; R.sup.2 and R.sup.5 are an aryl group, a heteroaryl group, an alkyl group, or an alkenyl group; R.sup.3 and R.sup.4 are an alkyl group or an alkenyl group, R.sup.6 is an aryloxy group, a heteroaryloxy group, an alkyloxy group, or an alkenyloxy group)].

[Chemical Formula 1]

A.sup.1G.sup.1(2)

A.sup.1SF.sub.5(1)

The present invention provides a production method capable of efficiently synthesizing an SF.sub.5 group-containing compound, or the like. The present invention is a method for synthesizing an SF.sub.5 group-containing compound represented by the general formula (1) from a thioaryl compound represented by the general formula (2) [A.sup.1 is an aryl group or a heteroaryl group; G.sup.1 is SH, SCN, SF.sub.3, SSR.sup.1, SCOR.sup.2, SR.sup.3, SF.sub.2R.sup.4, SSi(R.sup.5).sub.3, SPO(R.sup.6).sub.2, (N-phthalimidyl)thio group, or a thianthrenium group (R.sup.1 is an aryl group or a heteroaryl group; R.sup.2 and R.sup.5 are an aryl group, a heteroaryl group, an alkyl group, or an alkenyl group; R.sup.3 and R.sup.4 are an alkyl group or an alkenyl group, R.sup.6 is an aryloxy group, a heteroaryloxy group, an alkyloxy group, or an alkenyloxy group)].

[Chemical Formula 1]

A.sup.1G.sup.1(2)

A.sup.1SF.sub.5(1)

Bivalent linkers to be included in or for preparing vitamin, drug, diagnostic agent, and/or imaging agent conjugates are described.

Bivalent linkers to be included in or for preparing vitamin, drug, diagnostic agent, and/or imaging agent conjugates are described.

The present invention relates to a benzamide compound and a preparation method, use and pharmaceutical composition thereof. The benzamide compound represented by formula (I) is a STAT3 inhibitor, and can be used to prevent and/or treat a disease related to STAT3 activity, such as a tumor, autoimmune disease, renal disease, cardiovascular disease, inflammation, metabolic/endocrine dysfunction, and neurological disease.

##STR00001##

The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.

##STR00001##

The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.

##STR00001##

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: ##STR00001##
The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured:

##STR00001## or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors and 15-PGDH activators described herein.